Federal actions taken in May could lead to curtailed use of biologics for treating anemia associated with certain cancers.
On May 10, members of the Oncologic Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted 15 to 2 in favor of recommending new restrictions on the use of genetically engineered erythropoiesis-stimulating agents (ESAs) in patients with cancer. The advisory committee also voted (17 to 0) to call for new safety studies for ESA use for patients with cancer.
Mitka M. New Limits Advised for Anemia Drugs. JAMA. 2007;297(22):2464. doi:10.1001/jama.297.22.2464